Follicular lymphoma is an incurable malignancy 1 , with transformation to an aggressive subtype representing a critical event during disease progression. Here we performed whole-genome or whole-exome sequencing on 10 follicular lymphoma-transformed follicular lymphoma pairs followed by deep sequencing of 28 genes in an extension cohort, and we report the key events and evolutionary processes governing tumor initiation and transformation. Tumor evolution occurred through either a 'rich' or 'sparse' ancestral common progenitor clone (CPC). We identified recurrent mutations in linker histone, JAK-STAT signaling, NF-κB signaling and B cell developmental genes. Longitudinal analyses identified early driver mutations in chromatin regulator genes (CREBBP, EZH2 and KMT2D (MLL2)), whereas mutations in EBF1 and regulators of NF-κB signaling (MYD88 and TNFAIP3) were gained at transformation. Collectively, this study provides new insights into the genetic basis of follicular lymphoma and the clonal dynamics of transformation and suggests that personalizing therapies to target key genetic alterations in the CPC represents an attractive therapeutic strategy.
Follicular lymphoma, the most common indolent non-Hodgkin lymphoma, remains a significant clinical burden, as the majority of affected individuals undergo multiple relapses and eventually develop resistance to standard therapies. Furthermore, in a subset of individuals, follicular lymphoma transforms into the more aggressive diffuse large B cell lymphoma (DLBCL), with this transformation associated with poor clinical outcomes [2] [3] [4] . Recent genetic profiling and case studies of donor-derived follicular lymphoma following stem cell transplantation suggest the putative existence of a 'long-lived' tumorinitiating progenitor cell compartment from which successive disease events occur [5] [6] [7] [8] . An in-depth characterization and chronicling of the underlying genetic events from follicular lymphoma to transformed follicular lymphoma will serve as a guide in the development of effective targeted therapies. To address this need, we conducted whole-genome or whole-exome sequencing of sequential follicular lymphoma-transformed follicular lymphoma (FL-tFL) pairs and matched germline samples from 10 cases (Fig. 1a and Online Methods), with deep targeted sequencing of 28 genes in an extension cohort ( Supplementary Fig. 1 and Supplementary Table 1) .
For the ten index cases (six whole-genome sequenced and four whole-exome sequenced), the sequencing yielded mean genomic and exonic coverage of 37× and 110×, respectively, with 96% of the targeted bases covered by >10-fold (Supplementary Table 2 ). In the 6 wholegenome sequenced cases, we detected approximately 10,000 somatic variants per tumor (Supplementary Table 3 ). G>A/C>T transitions were the most common nucleotide substitutions, consistent with data from other cancer types (Supplementary Fig. 2a ). We observed a higher frequency of transversions in the transformation-specific variants (P = 0.006; Fig. 1b and Supplementary Fig. 2b ), reflected in the lower transition/transversion (Ti/Tv) ratios for transformed samples (P = 0.008; Supplementary Fig. 2c ). Focusing on protein-altering changes, we identified between 21 and 143 nonsynonymous somatic Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma variants per sample, with an increased frequency of mutations present after transformation in the majority of cases (Supplementary Fig. 3 ). In total, 1,560 protein-altering variants affecting 908 genes were detected across the 10 cases, comprising missense changes (84.8%), short indels (8.9%) and nonsense mutations (6.3%) (Supplementary Table 4 ). We verified 235 single-nucleotide variants (SNVs) and 48 indels out of 293 variants, corresponding to 118 genes, thereby achieving concordance rates of 98% and 88%, respectively (Supplementary Table 5 ). Interrogation of the six whole-genome sequenced cases identified copy number alterations (CNAs), previously unreported structural variants, fusion transcripts and recurrent mutations in noncoding regions (5′ UTRs, 3′ UTRs and promoter regions) ( Supplementary Fig. 4 and Supplementary Table 6 ).
To determine the evolutionary relationship between the 10 paired follicular lymphoma-transformed follicular lymphoma samples, we constructed phylogenetic trees for each case using the somatic variants detected (only nonsynonymous variants and all variants). Each tree showed branching rather than linear evolution, with the 'trunk' representing genetic events shared by the follicular lymphoma tumor(s) and their paired transformed follicular lymphoma samples, thus supporting the presence of an ancestral CPC. Two distinct patterns of evolution from the CPC emerged. In the first pattern, all cases with the exception of S5 and S9 showed high clonal semblance between the paired follicular lymphoma and transformed follicular lymphoma tumors, and we refer to this pattern as evolution through a 'rich' ancestral CPC (Fig. 2a,b and Supplementary Figs. 5a-f and 6) . The mutations harbored in each CPC demonstrated an enrichment for genes involved in chromatin regulation, with concurrent mutations occurring in KMT2D (also known as MLL2), which encodes a histone methyltransferase responsible for histone H3 lysine 4 (H3K4) trimethylation, and other histone-modifying genes (CREBBP, EP300, EZH2 and MEF2B) [9] [10] [11] [12] . Apart from frequent mutations in histone modifiers, other mutational targets in the eight rich CPCs included genes involved in immune modulation (B2M, CD58 and TNFRSF14), JAK-STAT signaling (SOCS1 and STAT6) and B cell receptor (BCR)-NF-κB signaling (BCL10, CARD11 and CD79B), with many of these genes previously reported in DLBCL [10] [11] [12] [13] [14] [15] [16] . In contrast, a second, unique pattern of evolution was seen in cases S5 and S9, in which only four nonsynonymous mutations were shared by the follicular lymphoma and transformed follicular lymphoma samples (referred to as evolution through a 'sparse' CPC) (Fig. 2c,d) . Intriguingly, in both cases, different KMT2D (S5 and S9), TNFRSF14 (S5) and CREBBP (S9) mutations occurred in the diagnostic follicular lymphoma and transformed follicular lymphoma biopsies, appearing to have arisen from independent clones and reflecting a convergent pattern of evolution. These observations strongly support tumoral dependency on CREBBP, KMT2D and TNFRSF14 alterations during lymphomagenesis and progression.
To evaluate the mutation prevalence for the genes identified in our discovery cohort, we performed deep targeted resequencing of 28 candidate genes (mainly prioritizing genes involved in functional processes not previously implicated in follicular lymphoma ( Supplementary Tables 7 and 8) ) in an extension cohort of 100 independent follicular lymphoma biopsies and 32 paired follicular lymphoma-transformed follicular lymphoma cases (including the 10 index cases), achieving a mean depth of coverage of 840×. A prominent feature of the genetic landscape was the presence of mutations targeting genes involved in chromatin regulation through histones and histone modifications ( Fig. 3 and Supplementary Fig. 7 ), confirming previous studies [9] [10] [11] [12] . Notably, over 70% of cases had concurrent mutations in at least two of the histone-modifying enzymes screened (CREBBP, EZH2, MEF2B and KMT2D). KMT2D was mutated in 82% of our cohort, with approximately half of the cases harboring multiple mutations. Mutation frequencies for the histone acetyltransferase CREBBP and the histone methyltransferase EZH2 were higher than in earlier studies at 64% and 20%, respectively [9] [10] [11] .
Notably, linker histone genes were recurrently mutated in follicular lymphoma. These genes encode proteins that facilitate the folding of higher order chromatin structures and regulate the access of histonemodifying enzymes and chromatin-remodeling complexes to their target genes [17] [18] [19] . Overall, we observed mutations affecting at least one histone H1 gene in 28% of our series, with HIST1H1C and HIST1H1E being the most frequently mutated (Fig. 3 and Supplementary Table 9) . Most of the histone H1 alterations were missense and were clustered in the highly conserved globular domain (Supplementary Fig. 8 ), targeting residues directly involved in DNA binding [20] [21] [22] [23] Figure 1 Clinical timelines and somatic mutation profiles for the discovery cases. (a) Biopsy information with disease event timelines for the ten whole-genome or whole-exome sequenced follicular lymphoma (FL) cases. (b) Distribution of base substitution patterns for all somatic SNVs identified in the six paired follicular lymphoma-transformed follicular lymphoma (FL-tFL) genomes. Somatic SNVs for each case were sorted into three categories: shared (variants present in both follicular lymphoma and transformed follicular lymphoma samples), follicular lymphoma specific and transformed follicular lymphoma specific. Aberrant somatic hypermutation (aSHM) did not contribute to the majority of variants detected, with the exception of previously described gene targets (supplementary Fig. 9 ). The p.Ser102Phe alteration in histone H1 resulted in greatly impaired association with chromatin relative to wild-type protein ( Fig. 4a,b) , suggesting that the identified mutations most likely lead to a loss-of-function phenotype by reducing the binding affinities and residence times of the histone H1 subtypes in chromatin-compromising chromatin compaction and the regulation of specific genes.
We observed frequent mutations in components of the JAK-STAT signaling pathway, including in STAT6 (12%) and SOCS1 (8%) (Supplementary Fig. 10 ). Similar SOCS1 and STAT6 mutations have been described in other germinal center lymphomas 24, 25 and have been shown to contribute to constitutive STAT6 activation and the promotion of tumor cell survival in lymphoma cell lines [26] [27] [28] .
Constitutive activation of the antiapoptotic NF-κB signaling pathway, caused by mutations affecting positive and negative regulators of signaling, is an established feature of the activated B cell-like subtype of DLBCL (ABC DLBCL). In contrast, these mutations occur infrequently in germinal center B cell-like DLBCL In each case, a phylogenetic tree was constructed using nonsynonymous mutations and is shown against the corresponding event timeline. All trees have shared mutations (trunk), which represent a common ancestral origin from a CPC, and unique branches, depicting the mutations present in that biopsy alone. The length of individual branches denotes the number of mutations separating the two disease events. S2 (a) and S7 (b), both with three follicular lymphomas (blue) and a single transformed follicular lymphoma (red) biopsies, show divergent clonal evolution from a rich CPC pool (highlighted by the dashed lines) from which subsequent events arise. S5 (c) and S9 (d) show a sparse CPC (four shared mutations between follicular lymphoma and transformed follicular lymphoma samples in both cases) and convergent evolution, in which similar genetic alterations occur independently on separate branches of the tree. All paired tumors were confirmed to be clonally related through BCL2-IGH rearrangement analyses. The pattern of clonal evolution was identical with all types of somatic variants considered (supplementary Fig. 6 ).
Functional annotation of the genes was based on previously reported functions [10] [11] [12] [13] [14] [15] [16] . GL, germ line. KMT2D   2373  519  1166  1169  2618  1183  717  1701  1674  1281  2229  1246  586  1162  1803  2115  2296  1616  175  817  685  990  1702  1164  1231  1508  1627  1649  465  1165  1642  1652  1668  FL19  1283  2594  1180  1655  665  2119  1182  FL20  1282  804  1792  1987  1204  1666  1646  1801  2120  1669  1171  D01  1638  1153  1287  1754  2613  2655  464  585  1202  2601  1643  1647  1641  850  2299  1012  2105  1156  2121  1700  1152  525  623  1671  1289  626  FL18  1558  1645  1286  1699  2542  994  1124  1644  805  1357  1310  1637  1640  1663  1670  1675  2649  1673  2094   EZH2  MEF2B   HIST1H1B  HIST1H1C  HIST1H1D  HIST1H1E  HIST1H2AC  HIST1H2AG   HIST1H2BC   HIST1H2BD  HIST1H2BG  TNFRSF14  SOCS1  STAT6  STAT3  CARD11   TNFAIP3  BCL10  CD79A  CD79B  PRKCB  PLCG2  MYD88   EBF1  IKZF3 npg l e t t e r s (GCB DLBCL) 13, 14, 29, 30 . Interestingly, we detected mutually exclusive mutations in this pathway in one-third of follicular lymphomas, with a predilection for CARD11 (11%) and TNFAIP3 (11%) (Fig. 3) . The type and location of the detected aberrations were reminiscent of the mutations found in ABC DLBCL, with the exception of variants in CD79B (Supplementary Fig. 10 ), which included frameshift mutations affecting the immunoreceptor tyrosine-based activation motif (ITAM) domain in follicular lymphoma in contrast to the predominant missense mutations affecting the Tyr196 residue reported in ABC DLBCL 14 . A number of emerging therapeutic agents target the NF-κB signaling cascade, and such treatments may be beneficial to a preselected subset of patients with follicular lymphoma harboring mutations in this pathway. We identified mutations in genes important in B cell development in 17% of our cohort ( Fig. 3 and Supplementary Fig. 10 ). We focused on early B cell factor 1 (EBF1), a transcription factor frequently deleted in high-risk acute lymphoblastic leukemia 31 . The EBF1 protein functions as a homodimer and binds the consensus sequence 5′-TCCCNNGGGA-′3 (refs. 32,33) , and more than half of the mutations in our series affected conserved residues of the DNA-binding domain (DBD) (Fig. 4c) . Binding of EBF1 to target genes can elicit different responses, including transcriptional activation or repression or H3K4 dimethylation 34 . In particular, transcriptional activation of Igll1, encoding the λ5 surrogate light chain of the pre-B cell receptor, has been used as an assay to assess the binding and function of EBF1 (ref. 33 ). Therefore, we tested the effects of three Ebf1 mutations, encoding p.Gly171Asp and p.Ser238Thr (located in the DBD) and p.Arg381Ser (located in the helix-loop-helix (HLH) domain), on the ability to activate expression of the Ebf1 target genes Igll1 and Cd79b in Ebf1-deficient primary mouse pre-pro-B cells (Fig. 4d) . Gly171Asp and Ser238Thr mutant lines demonstrated markedly impaired upregulation of both Igll1 and Cd79b expression, most likely reflecting reduced binding to regulatory elements in their respective promoters. The HLH mutant, Arg381Ser, resulted in a more modest reduction in target gene expression. Taken together, the data suggest that the EBF1 mutations detected in follicular lymphoma lead to loss of function and a reduction in EBF1 target gene expression.
To discriminate early from late genetic events, we integrated variant allele frequencies (VAFs) generated from our high-depth sequencing data with SNP array copy number profiles for 29 cases (26 follicular lymphoma-transformed follicular lymphoma pairs and 3 diagnostic follicular lymphomas), using the ABSOLUTE algorithm 35 . This scheme allowed us to correct for variations in tumor content and ploidy as well as locus-specific CNAs, thereby establishing the accurate clonal or subclonal status of mutations in our 28 selected genes. Mutations present in nearly all tumor cells (clonal) would suggest early events and therefore represent initiating 'driver' genes. Our results showed that mutations in histone-modifying genes (KMT2D, CREBBP and EZH2) as well as mutations in STAT6 and TNFRSF14 were predominantly clonal events (Fig. 5a) . These results expand on the findings of a recent study implicating CREBBP mutation as an early event in follicular lymphoma 36 . Interestingly, many of these driver genes (CREBBP, KMT2D and TNFRSF14) harbored compound heterozygous mutations that were frequently accompanied by either deletions or acquired uniparental disomy (aUPD), serving as pathogenic mechanisms to render tumor cells homozygous for a npg l e t t e r s pre-existing abnormality (Supplementary Fig. 11 ). Moreover, our longitudinal analyses of paired follicular lymphoma-transformed follicular lymphoma samples demonstrated that mutations in these genes were stable and remained clonally dominant, irrespective of therapy, in the majority of cases as the disease progressed ( Fig. 5b and Supplementary Fig. 12 ), reaffirming that these mutations represent key events in the founding CPC that repopulates the tumor at transformation. Targeted resequencing in additional follicular lymphoma-transformed follicular lymphoma pairs confirmed the findings in our discovery cohort, demonstrating evolution predominantly occurring via rich CPCs (Supplementary Figs. 7 and 12) . We next evaluated the follicular lymphoma-transformed follicular lymphoma pairs for previously unreported transformationassociated events. Using copy number profiling, we found an increase in the number of regions affected by CNAs and, notably, an enrichment of particular CNAs at transformation, such as amplifications of EZH2, MDM2, MYC and REL (Supplementary Fig. 13 and Supplementary  Table 10 ). EBF1 mutations were acquired and were restricted to the transformation biopsies in 5 of 32 cases, with VAFs indicating clonal events (Fig. 5c) . Remarkably, we also found the acquisition of alterations affecting regulators of NF-κB signaling at transformation, which specifically included mutations in MYD88 and TNFAIP3 ( Fig. 5d and  Supplementary Fig. 12) . Four of the five MYD88 mutations identified were restricted to the transformation biopsy, with none harboring the p.Leu265Pro alteration common to other B cell lymphomas 30, 37 ( Supplementary Fig. 10) . In all cases, these 'progressor' variants did not exist in the antecedent follicular lymphoma biopsies, suggesting that they were gained during the most recent clonal expansion leading to the transformation event. The acquisition of these late genetic events underscores the need for temporal mutational profiling as we move toward an era of precision medicine. It was particularly striking that the time interval from the biopsy of the antecedent follicular lymphoma to transformation in these cases was brief (range of 0.27-2.41 years), raising the possibility that the acquisition of particular genetic events is selectively advantageous through promoting higher fitness for the clone that drives transformation.
In summary, we report the most comprehensive sequencing effort so far in follicular lymphoma. The mutational landscape of follicular lymphoma predominantly indicates epigenetic 'addiction' but highlights co-occurring aberrations in genes involved in B cell development as well as JAK-STAT and NF-κB signaling. By longitudinal profiling, we provide unequivocal evidence for a reservoir ancestral population, enriched in early mutations in driver genes, that propagates successive disease events. We did not identify a single compelling genetic event responsible for transformation but instead demonstrate that the acquisition of distinct genetic alterations may prompt the onset of aggressive disease. The high frequency of relapse suggests that CPCs are resistant to standard therapies and that adopting a stratified treatment approach targeting the specific early genetic lesions identified in the putative CPC may ultimately offer the best chance of eradicating these cells and curing follicular lymphoma.
URLs. CASAVA, http://support.illumina.com/sequencing/ sequencing_software/casava.ilmn; PHYLIP package, http://evolution. genetics.washington.edu/phylip.html; Affymetrix Genome-Wide Human SNP Array 6.0, http://www.affymetrix.com/support/technical/ byproduct.affx?product=genomewidesnp_6.
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Methods and any associated references are available in the online version of the paper.
Accession codes. Sequencing data have been deposited in the European Genome-phenome Archive (EGA) under accession EGAS00001000399. Affymetrix SNP 6.0 data have been deposited in the Gene Expression Omnibus (GEO) under accession GSE42525. 
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Case samples. Ten individuals with follicular lymphoma were selected on the basis of the availability of sequential tumor lymph node biopsies (a sample with follicular lymphoma and a subsequent sample with histological transformation to DLBCL (transformed follicular lymphoma)) and matched germline samples consisting of remission bone marrows or peripheral blood specimens. Clonality for each of the paired follicular lymphoma and transformed follicular lymphoma samples was confirmed by BCL2-IGH breakpoint analysis, as previously described 40 . The clinical characteristics of these cases are presented in Supplementary Table 1 . Overall, 34 samples (10 paired follicular lymphomatransformed follicular lymphoma-germline samples and 2 additional relapsed follicular lymphoma samples for cases S2 and S7) were evaluated. An extension cohort of 22 additional paired follicular lymphoma and transformed follicular lymphoma samples and 100 independent follicular lymphoma cases were included in our validation experiments (Supplementary Table 8 ). All biopsies were previously histologically reviewed to confirm diagnosis and tumor content before DNA extraction from fresh-frozen tumor samples. Tumor content was further estimated using the ABSOLUTE 35 Whole-genome sequencing. Genomic DNA (5 µg) from matched tumor and germline samples was fragmented to generate libraries with an average insert size of 300 bp and sequenced using the HiSeq 2000 platform with paired-end reads of 100 bp, according to the manufacturer's protocols (Illumina). Detailed coverage data for all cases are shown in Supplementary Table 2 .
Whole-genome sequencing read mapping and somatic mutation detection. Raw sequencing data were aligned to the reference human genome (hg19) using the Illumina ELANDv2 aligner. Alignments were sorted and converted to BAM format. PCR duplicates were removed, and clusters of poorly aligned and anomalous reads were de novo assembled into contigs using the CASAVA (v1.8) package (see URLs). We implemented the Strelka algorithm 42 to identify somatic SNVs and indels for matched tumor-germline samples, selecting this algorithm for its sensitivity of mutation detection with varying tumor purities. After candidate indel detection and realignment, we called somatic variants and performed filtering. Only somatic calls originating from homozygous reference alleles in normal samples were considered.
A joint somatic quality score (Q) of ≥15 for SNVs and ≥30 for indels was applied for all calls retained after filtering. The complete list of variants is detailed in Supplementary Table 4 .
Whole-exome sequencing and analysis. Capture libraries were constructed from 3 µg of tumor and germline DNA using the Agilent SureSelect XT Human All Exon V4 kit. Enriched exome libraries were multiplexed and sequenced on the Illumina HiSeq 2500 platform to generate 100-bp pairedend reads (Supplementary Table 2 ). Sequencing reads were aligned to the reference genome using Burrows-Wheeler Aligner (BWA) 43 . SAM to BAM conversion and marking of PCR duplicates were performed using Picard tools (version 1.86), followed by local realignment around indels and base quality score recalibration using the Genome Analysis Toolkit (GATK) 44 (v2.3.9) . Somatic SNVs and indels were identified using the Strelka pipeline.
Annotation and recurrently mutated genes. All somatic SNVs and short indels retained after filtering were annotated using the SNPnexus tool 45 . The Ensembl database (v63) was used for gene and transcript identification and the detection of amino acid changes. Any variants overlapping with common and germline polymorphisms present in the dbSNP132 and HapMap databases were masked. The allele frequencies for individual variants in both germline and tumor samples were determined by read count. Somatic variants identified with both whole-genome and whole-exome sequencing are included in Supplementary Table 4 .
Copy number and structural variant analyses from whole-genome sequencing data. CNAs were identified using VarScan2 (ref. 46) (v2.3.5), with each tumor sample compared to the matching germline sample. Samples were segmented using the circular binary segmentation (CBS) algorithm 47 implemented in the R Bioconductor package DNAcopy (v2.12), which allowed splits to be reversed if the copy number ratio for tumor and normal samples was within 3 s.d. Structural variants were called using Pindel 48 (v0.2.4t) , with the exception of translocations, which were called using default parameters. Only calls that had no supporting reads in the normal sample but had ≥8 supporting reads in the tumor sample were retained. Translocations (fusion transcripts) were identified using the DELLY 49 and Breakdancer 50 algorithms on pairedend reads, only retaining structural variants called by both methods with ≥5 supporting reads in the tumor sample.
Identification of recurrent mutations in promoter regions. Using Ensembl gene and transcript annotations, the somatic variants in the region from −2,000 to +250 bp (within the 5′ UTR) relative to the transcription start site (TSS) for each transcript of protein-coding genes were identified across whole-genome sequencing data for all cases. Promoter regions recurrently mutated in multiple cases were identified, and mutation hotspots in these regions were also noted (Supplementary Table 6 ).
Mutation and indel validation. SNVs and indels were confirmed by bidirectional Sanger sequencing, fluorescence-based fragment size analysis or targeted deep sequencing (Fluidigm-MiSeq) as detailed below (Supplementary Table 5 ). Concordance data for selected variants called by whole-genome sequencing, whole-exome sequencing and validation targeted deep sequencing with estimated VAFs are shown in Supplementary Figure 14 .
Phylogenetic analysis. Evolutionary trees were constructed for each of the ten cases analyzed from whole-genome or whole-exome sequencing data on the basis of the distance matrix between germline, follicular lymphoma and transformed follicular lymphoma samples derived from the numbers of somatic variants (all variants as well as nonsynonymous SNVs and indels) from each biopsy, using the neighbor-joining algorithm 51 implemented in the PHYLIP package (see URLs). Once the consensus phylogenetic tree was determined, it was redrawn starting from germline and leading to the putative CPC, then progressing to the follicular lymphoma and transformed follicular lymphoma samples, with the branch length proportional to the number of somatic changes, i.e., genetic distance, between the samples. Trees were plotted against the clinical timelines.
High-density SNP arrays. Copy number analysis and identification of regions of copy-neutral loss of heterozygosity (cnLOH, also known as aUPD) were performed on a cohort of 26 paired follicular lymphoma-transformed follicular lymphoma and 3 diagnostic follicular lymphoma DNA samples (including 7 of our discovery cases) using Affymetrix SNP 6.0 microarrays. Further details are given in the Supplementary Note.
Targeted resequencing. Twenty-eight candidate genes (Supplementary Table 8) were sequenced in the extension cohort cases using the Access Array platform (Fluidigm). All samples were screened in duplicate, with a number of matched germline and normal tonsil DNA samples included as controls in each run. Access Array amplification was performed in a multiplex format with genomic DNA (50 ng) according to the manufacturer's recommendation. Deep sequencing was performed on multiplexed library pools using the Illumina MiSeq platform. After demultiplexing and FASTQ file generation for the raw data, reads were aligned to the reference genome using the Bowtie2 algorithm 52 . SAMtools 53 was used to generate sorted BAM files for each sample, and the VarScan2 tool was used to examine the pileup file to call variants, including SNPs and short indels, implementing a minimum threshold VAF of 5% and Fisher's exact test P value of <0.05. Only bases meeting the minimum base quality score of 20 from reads meeting the minimum mapping quality score of 20 were considered. A minimum read depth of 10 at a position was required to make calls, and variants with >90% of reads supporting one strand were excluded. Only concordant variants present in both duplicates or confirmed by independent Sanger sequencing were retained. Identified variants were annotated using SNPnexus to exclude variants reported in dbSNP132 and to identify variants that had nonsynonymous consequences or affected splice sites.
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Estimating the clonality of mutations. Tumor purity, ploidy and absolute DNA copy numbers were determined from Affymetrix SNP 6.0 data (n = 26 follicular lymphoma-transformed follicular lymphoma pairs and 3 diagnostic follicular lymphomas) by implementing the ABSOLUTE algorithm (Supplementary Table 11 ). The ASCAT algorithm was also used to determine tumor purity and ploidy to ensure high concordance across both algorithms (Supplementary Table 11 ). These estimates were used to compute and classify individual somatic mutations obtained from our deep sequencing analyses as clonal or subclonal on the basis of the posterior probability that the cancer cell fraction (CCF) exceeded 0.95, as previously reported 54 (Supplementary Table 12 ).
Identification of recurrent targets of aberrant somatic hypermutation. SHM hotspots typically occur within the 2-kb window downstream of the TSS, and we focused our analyses on these regions 55 . The total number of SNVs and the average mutation density across the 14 whole-genome sequenced tumor samples were investigated. For each gene, the ratio of transition to transversion mutations, the ratio of mutations at C:G to A:T sites and the percentage of SNVs within the hotspot motif WRCY, their associated P values and the SHM indicator were calculated in accordance with previous studies 56 . The probability of observing the actual number of SNVs or more for each target gene was calculated on the basis of the Poisson distribution given the expected number of SNVs per SHM target region if those SNVs were uniformly randomly distributed in all target genes. A list of SHM gene targets is included in Supplementary Table 13 .
EBF1 mutagenesis, retroviral expression and target gene analysis. Three follicular lymphoma-derived mutants (p.Gly171Asp and p.Ser238Thr alterations were located in the DBD, and p.Arg381Ser was located in the HLH domain) were generated to assess their ability to activate Ebf1 target gene expression. Ebf1-deficient pre-pro-B cell lines (cultured on OP9 feeders in the presence of IL-7, Flt3 ligand and stem cell factor (SCF)) were transduced with bicistronic retroviruses expressing wild-type or mutant Ebf1-GFP as described previously 34 . GFP-positive cells were sorted 24 h after transduction, and expression was confirmed by immunoblotting (data not shown). Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. qRT-PCR analysis was performed in triplicate on a 7500 Fast Real-Time PCR system (Applied Biosystems) using Power SYBR Green master mix to measure the mRNA levels of the Ebf1 target genes Igll1 and Cd79b (refs. 33,34) .
Generation of clones overexpressing wild-type and Ser102Phe histone H1c in histone H1c-histone H1d-histone H1e triple-knockout ESCs. Expression plasmids encoding Flag-tagged wild-type or Ser102Phe human histone H1c were constructed by replacing the mouse histone H1d coding sequence with the sequence encoding Flag-tagged wild-type or mutant human histone H1c in a 5-kb fragment encompassing the mouse Hist1h1d upstream and downstream regulatory sequences, which were inserted into a vector containing a blasticidin-resistant gene. Plasmid DNA (20 µg) was transfected into 2 × 10 7 histone H1 triple-knockout ESCs, as previously described 57 . A total of 48 clones (24 clones for transfection with each vector) resistant to blasticidin were picked and screened by immunoblotting using an anti-Flag antibody (Sigma-Aldrich, F1804; 1:2,000 dilution). Cell clones with the highest levels of expression of Flag-tagged wild-type and mutant histone H1c were selected for further analysis. (Supplementary Fig. 9 )
Preparation and analysis of histones. Chromatin was prepared from ESCs, and histones were extracted with 0.2 N sulfuric acid, according to previously described protocols 38, 39, 58 . Approximately 50 µg of total histones was injected into a C18 reverse-phase column (Vydac) on an AKTA UPC10 system (GE Healthcare). Effluent was monitored at 214 nm, and peak areas were analyzed with AKTA UNICORN (v5.11) software. Absorbance at 214 nm for the histone H1 and H2B peaks was adjusted according to the respective peptide bonds, and the histone H1/nucleosome ratio was calculated as previously described 39, 58 .
